NSE: LAURUSLABS | BSE: 540222

Strong Performer, Getting Expensive

Download real time

756.75 10.70 (1.43%)

New 52W High today

4.1M NSE+BSE Volume

NSE 02 Jul, 2025 3:31 PM (IST)

40,851.2

Market Cap

High in industry

1.2

Beta 1Year

Very High Volatility

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

29 Jul 2024

756.75

1.43%

Laurus Labs Limited

Neutral: Laurus Labs Ltd.

Target

Keynote Capitals Ltd

Quarterly Update Q1FY25

Laurus Labs Ltd. has gained 12.96% in the last 1 Week

Laurus Labs Ltd.

29 Jul 2024

756.75

1.43%

Gross margins improvement to fuel earnings growth

Buy: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs (LAURUSLABS) delivered a weak Q1FY25 due to lower revenue recorded in CDMO, FDFs and Bio and outperformance in generic APIs vs. our estimates.
The API outperformed due to strong growth in oncology and other APIs. Gross margins improved, however, due to improved products mix, process improvements in large value APIs and reduced raw material costs.

Laurus Labs Ltd. has gained 23.83% in the last 1 Month

Laurus Labs Ltd.

25 Jul 2024

756.75

1.43%

Lower ARV formulations and reduced operating leverage hurt earnings

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Labs (LAURUS) posted a weak 1QFY25 due to deviation in buying of ARV formulations and deferral of some orders in the other API segment.

Laurus Labs Ltd. has gained 23.43% in the last 6 Months

Laurus Labs Ltd.

29 Apr 2024

756.75

1.43%

Laurus Labs Limited

Neutral: Laurus Labs Ltd.

Recommendation Target

Keynote Capitals Ltd

Quarterly Update Q4FY24

Laurus Labs Ltd. has gained 23.43% in the last 6 Months

Laurus Labs Ltd.

29 Apr 2024

756.75

1.43%

CDMO and Bio to drive profitability

Buy: Laurus Labs Ltd.

Recommendation Target

KRChoksey

Laurus Labs (LAURUSLABS) met our estimates on revenue, EBITDA margins and PAT front for both Q4FY24 and FY24; however, underperformed on GPM in Q4FY24 and marginally underperformed on the same in FY24. Notably, higher value CDMO and custom synthesis segment witnessed 3.5% Y-o-Y (+11.3% Q-o-Q) rise in revenue in Q4FY24 after 4 consecutive quarters of decline seen due to waning of high base effect.

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

25 Apr 2024

756.75

1.43%

Product mix and reduced operating leverage hurt profitability

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Labs (LAURUS) delivered better-than-expected revenue in 4QFY24.
However, EBITDA/PAT missed our estimates due to lower sales in the CDMO
segment and weak pricing in the other API segment.

Laurus Labs Ltd. has gained 24.25% in the last 3 Months

Laurus Labs Ltd.

29 Jan 2024

756.75

1.43%

First Light | Bajaj Auto, TVS Motor, SBI Card, Laurus Labs, Cipla, Mahanagar Gas, DCB Bank, SBI Life

Sell: Laurus Labs Ltd.

BOB Capital Markets Ltd.

BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership

Laurus Labs Ltd. has an average target of 649.60 from 5 brokers.

Laurus Labs Ltd.

29 Jan 2024

756.75

1.43%

Momentum in FDF, Bio and Oncology APIs strong, to aid in growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue declined 22.6% Y-o-Y (-2.4% Q-o-Q) to Rs. 11,949 Mn (vs. our estimate of Rs. 12,669, miss of 5.7%) in Q3FY24. The generic API sales declined at 9.2% Y-o-Y (-8.7% Q-o-Q) to Rs. 5,740 Mn (vs. our estimate of Rs. 6,627 Mn, a miss 13.4%) due to high base effect as anticipated with the loss of Paxlovid opportunity in the current period, that took place during Q4FY22-Q3FY23.